• 1
    Luessenhop CP, Higgins LD, Brause BD, Ranawat CS.Multiple prosthetic infections after total joint arthroplasty: risk factor analysis.J Arthroplasty1996;11:8628.
  • 2
    Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, et al.Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis.Arthritis Rheum2008;59:171320.
  • 3
    Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al.Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis.Arthritis Rheum2006;55:3337.
  • 4
    Den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al.Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.J Rheumatol2007;34:68995.
  • 5
    Kawakami K, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, Yano K, et al.Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-α blockers: perioperative interruption of tumour necrosis factor-α blockers decreases complications?Rheumatology (Oxford)2010;49:3417.
  • 6
    Momohara S, Hashimoto J, Tsuboi H, Miyahara H, Nakagawa N, Kaneko A, et al.Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study.Mod Rheumatol2013;23:4409.
  • 7
    Mariette X, Gottenberg JE, Ravaud P, Combe B.Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.Rheumatology (Oxford)2011;50:2229.
  • 8
    Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al, on behalf of the Investigators of the AutoImmunity and Rituximab Registry and the French Society of Rheumatology.Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the AutoImmunity and Rituximab registry.Arthritis Rheum2010;62:262532.
  • 9
    Saech J, Maizus K, Owczarczyk K, Roehrs T, Benenson E, Rubbert A.Rituximab in patients with rheumatoid arthritis and surgical intervention [abstract].Ann Rheum Dis2009;68 Suppl:443.
  • 10
    Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM.T cell homeostasis in patients with rheumatoid arthritis.Proc Natl Acad Sci USA2000;97:92038.
  • 11
    Sibilia J, Gottenberg JE, Mariette X.Rituximab: a new therapeutic alternative in rheumatoid arthritis.Joint Bone Spine2008;75:52632.
  • 12
    Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, et al.B cells in systemic sclerosis: a possible target for therapy.Autoimmun Rev2011;10:62430.
  • 13
    Hayata K, Kanbe K, Chiba J, Nakamura A, Inoue Y, Hobo K.Clinical factors related to the efficacy and complications of orthopedic surgery for rheumatoid arthritis with infliximab.Int J Rheum Dis2011;14:316.
  • 14
    Wendling D, Balblanc JC, Brousse A, Wendling D, Balblanc JC, Brousse A et al.Surgery in patients receiving anti-tumour necrosis factor α treatment in rheumatoid arthritis: an observational study on 50 surgical procedures [letter].Ann Rheum Dis2005;64:13789.
  • 15
    Pham T, Fautrel B, Gottenberg JE, Goupille P, Hachulla E, Masson C, et al.Rituximab (MabThera) therapy and safety management: clinical tool guide.Joint Bone Spine2008;75 Suppl:S199.